Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 known ✓ | P22748 | 3/20 | 0.33 |
| ▸ | CA1 known ✓ | P00915 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL27192514 | 0.95 | CYP4F2 (0.32) | CYP4F2CYP4A11 | |
| Potassium Ion SCHEMBL1724809 | 0.95 | CYP4F2 (0.32) | CA4CA1CYP4F2CYP4A11 | |
| SCHEMBL9837399 | 0.85 | CYP4F2 (0.47) | CA4CA1CYP4F2CYP4A11 | |
| SCHEMBL2590356 | 0.79 | FFAR3 (0.42) | CA4CA1FFAR3HDAC3HDAC1 | |
| SCHEMBL1082921 | 0.78 | ACLY (0.38) | CA4CA1CYP4F2CYP4A11 | |
| SCHEMBL3957769 | 0.78 | — | — | |
| SCHEMBL6931562 | 0.77 | FFAR3 (0.46) | CA4CA1FFAR3HDAC3HDAC1 | |
| SCHEMBL28394389 | 0.76 | ACLY (0.37) | CA1CYP4F2CYP4A11 | |
| SCHEMBL4459363 | 0.76 | ACLY (0.37) | CA1CYP4F2CYP4A11 | |
| SCHEMBL31407802 | 0.76 | CA2 (0.36) | CA4CA1FFAR3HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119285572-A | Kinase inhibitors and uses thereof | 戴纳立制药公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2025-01-09 | — | — | US | disclosed |
| CN-119264073-A | Kinase inhibitors and uses thereof | 戴纳立制药公司 | 2025-01-07 | — | — | CN | disclosed |
| US-12129263-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2024-10-29 | — | — | US | disclosed |
| CN-110913858-B | Kinase inhibitors and uses thereof | 戴纳立制药公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20220041620-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2022-02-10 | — | — | US | disclosed |
| US-11203600-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3624797-A1 | KINASE INHIBITORS AND USES THEREOF | Denali Therapeutics Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2020-03-19 | — | — | US | disclosed |
| WO-2018213632-A1 | KINASE INHIBITORS AND USES THEREOF | DENALI THERAPEUTICS INC. (US) | 2018-11-22 | — | — | WO | disclosed |
| EP-0211416-B1 | NOVEL HMG-COA REDUCTASE INHIBITORS | MERCK & CO. INC. (US) | 1991-10-16 | — | — | EP | disclosed |
| US-4851436-A | ANTICHOLESTEROL AND ANTILIPEMIC AGENTS | MERCK & CO., INC. (US) | 1989-07-25 | — | — | US | disclosed |
| US-4668699-A | 6-(NAPHTHYLETHYL)TETRAHYDROPYRAN-2-ONES; ANTILIPEMIC, ANTICHOLESTEROL | MERCK & CO., INC. (US) | 1987-05-26 | — | — | US | disclosed |
| US-4665091-A | 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A, ANTICHOLESTEROL | MERCK & CO., INC. (US) | 1987-05-12 | — | — | US | disclosed |
| EP-0211416-A2 | Novel HMG-CoA reductase inhibitors | MERCK & CO. INC. (US) | 1987-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | CA4 4342/4885CA1 4497/4885CYP4F2 3293/4885 |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | CA4 4342/4885CA1 4497/4885CYP4F2 3293/4885 |
| US-11203600-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | CA4 4342/4885CA1 4497/4885CYP4F2 3293/4885 |
| US-20220041620-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | CA4 4342/4885CA1 4497/4885CYP4F2 3293/4885 |
| US-12129263-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | CA4 4342/4885CA1 4497/4885CYP4F2 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.